Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06850298

H5N1 Milk Detection Study

The purpose of this study is to determine whether drinking pasteurized milk (milk heated to kill harmful germs) that contains inactive particles of a flu virus called A(H5) could lead to the detection of the virus in the nose or throat. Inactive particles are not capable of causing disease. The results will help the Centers for Disease Control and Prevention (CDC) better understand how milk consumption could affect flu surveillance. Investigators also want to see if the body produces antibodies in response to this milk consumption.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hope Clinic

Atlanta, Georgia, 30322, United States

Location status: Recruiting

Location contact

Daniel Graciaa, MD

PRINCIPAL_INVESTIGATOR

Daniel Graciaa, MD, MPH, MSc

CONTACT

[email protected]

404-712-1370

About this study

Since March 2024, avian influenza A (H5N1) viruses have infected U.S. dairy cattle and spread widely. The virus has been identified in high concentrations in raw milk, and research shows that pasteurization - the process of heating milk to a specific temperature for a set time - inactivates the A (H5N1) virus. Therefore, the Food and Drug Administration (FDA) says that commercial pasteurized milk is safe for consumption. However, trace amounts of inactive influenza particles may still be detected in pasteurized milk.

This study aims to determine whether drinking pasteurized milk could be a possible exposure for H5N1 influenza detection. The findings will support the Centers for Disease Control and Prevention's (CDC) efforts to evaluate milk consumption as a factor in influenza surveillance and provide context for interpreting surveillance data.

Healthy adults will drink 250 mL of pasteurized milk containing the inactive H5N1 virus, provided by the CDC, either during a single visit or over three consecutive daily visits. Nasal and combined nasal/oral swabs will be collected immediately following milk consumption to assess the presence of influenza. Additionally, a subset of participants will provide blood, saliva, and stool samples at the initial visit and again 21-30 days post-consumption.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals aged 18-64 years
  • BMI ≤ 35 kg/m2
  • Able to understand and give informed consent (American English) and comply with study visits and procedures.
  • In good general health based on medical history and the investigator's clinical judgment.

Exclusion criteria

  • Symptoms of acute respiratory illness or conjunctivitis within 7 days
  • Febrile illness in the previous 72 hours
  • Recent influenza antiviral use (within 14 days)
  • Immunosuppression due to illness or medications
  • Current pregnancy or breastfeeding
  • History of allergy or intolerance to milk or milk alternatives
  • Consumption of raw (unpasteurized) milk within the previous 14 days
  • Recent work (within 14 days) on a farm with animals known to be infected with A(H5) virus
  • Previous receipt of A(H5) vaccine at any time

Treatment and study plan

Pasteurized milk contaminated with killed A(H5) virus

Other

Milk to be used in the study will be obtained from the CDC. Pasteurized commercial milk likely to contain detectable A(H5N1) particles will be obtained from a source such as a recently affected dairy farm. The CDC Influenza Division laboratory (Viral, Surveillance, and Diagnosis Branch) will test the milk to confirm the presence of viral A(H5) RNA using a protocol developed and validated by the US FDA Agricultural Research Service. The US Food and Drug Administration (FDA) has indicated that the consumption of commercial pasteurized dairy products in the US is safe.

Primary outcomes

  1. Proportion of respiratory specimens with influenza detected

    Time frame: Up to 30 days after milk consumption

    Proportion of respiratory specimens (nasopharyngeal and combined nasal/oropharyngeal swabs) with detection of influenza after consumption of pasteurized milk contaminated with killed A(H5) virus

Secondary outcomes

  1. Severe adverse events after milk consumption

    Time frame: Up to 30 days after milk consumption

    Participants will be asked to call the site if they develop any adverse events for the entire the study participation.

Study contacts

Contact information is provided by the study sponsor or research team.

Daniel Graciaa, MD, MPH, MSc

CONTACT

[email protected]

404-712-1370

Sponsors and collaborators

Lead sponsor

Emory University

Other

Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

Registry information

Official study title

Investigation of Impact of Milk Consumption on H5 Influenza Detection in Respiratory Specimens

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Feb 27, 2025
Registry last updated
Apr 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.